Andros Pharmaceuticals Co.,Ltd
Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment… Read more
Andros Pharmaceuticals Co.,Ltd - Asset Resilience Ratio
Andros Pharmaceuticals Co.,Ltd (6917) has an Asset Resilience Ratio of 59.05% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Andros Pharmaceuticals Co.,Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Andros Pharmaceuticals Co.,Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$233.80 Million | 59.05% |
| Total Liquid Assets | NT$233.80 Million | 59.05% |
Asset Resilience Insights
- Very High Liquidity: Andros Pharmaceuticals Co.,Ltd maintains exceptional liquid asset reserves at 59.05% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Andros Pharmaceuticals Co.,Ltd Industry Peers by Asset Resilience Ratio
Compare Andros Pharmaceuticals Co.,Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Andros Pharmaceuticals Co.,Ltd (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Andros Pharmaceuticals Co.,Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 71.16% | NT$314.17 Million | NT$441.48 Million | +38.36pp |
| 2023-12-31 | 32.81% | NT$173.59 Million | NT$529.15 Million | -17.71pp |
| 2022-12-31 | 50.52% | NT$166.50 Million | NT$329.60 Million | +6.41pp |
| 2021-12-31 | 44.11% | NT$53.05 Million | NT$120.27 Million | -7.37pp |
| 2020-12-31 | 51.48% | NT$78.95 Million | NT$153.35 Million | -4.25pp |
| 2019-12-31 | 55.73% | NT$104.09 Million | NT$186.78 Million | -- |